Rifampicin plus isoniazid showed no clear difference in hepatotoxicity compared with isoniazid (low certainty).
It is very uncertain whether rifampicin plus pyrazinamide changes adherence compared with isoniazid (very low certainty).
Rifampicin plus pyrazinamide leads to higher treatment‐limiting adverse events compared with isoniazid (high certainty).
Rifampicin plus pyrazinamide probably leads to higher hepatotoxicity compared with isoniazid (moderate certainty).
It is very uncertain whether rifampicin plus pyrazinamide changes active TB: compared with isoniazid (very low certainty).
Doxycycline+Rifampicin probably leads to higher total treatment failure compared with doxycycline+Streptomycin (moderate certainty).
Doxycycline+Rifampicin showed no clear difference in minor adverse drug reactions compared with doxycycline+Streptomycin (low certainty).
It is very uncertain whether oral isoniazid plus rifampicin changes clinical failure clinical observation compared with no intervention (very low certainty).
It is very uncertain whether rifampicin combined with streptomycin changes recurrence, 12 months compared with surgery alone (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether summary of findings table ‐ Rifampin/rifampicin changes risk for at least one adverse event per patient compared with placebo (very low certainty).